US FDA's Dual Approvals: A Cancer Breakthrough and Expanded Access to Diabetes and Weight-Loss Drugs

The U.S. FDA has approved Adaptimmune's therapy, Tecelra, for treating synovial sarcoma, a rare cancer affecting young people. Additionally, all doses of Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are now available, although they remain on the FDA's shortage list.

The U.S. Food and Drug Administration has approved Adaptimmune's pioneering therapy, Tecelra, for treating synovial sarcoma, a rare and potentially life-threatening cancer of the soft tissues, primarily affecting young people.

In other news, the FDA announced that all doses of Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are now available. Despite this, the drugs are still listed on the FDA's shortage list, indicating ongoing supply issues.

This dual announcement marks significant progress in both cancer treatment and the management of diabetes and weight loss, reflecting the FDA's efforts to address critical health needs.

(With inputs from agencies.)